Effects of chitosan on serum cytokine levels in elderly subjects.
This study was done to evaluate the immune enhancing activity of health function food, chitosan by clinical study. To evaluate the effect of chitosan on serum cytokine levels in elderly adults, 5.1 g/day of chitosan was administrated to volunteers (age range 74 approximately 86, mean 80 +/- 3 year old) for 8 weeks. This study was IRB approved and all patients gave informed consent prior to examination. The clinical study showed that the increase of IL-2, IL-12, and TNF-alpha production were a little greater in chitosan administered group as in the control group but there were no significant differences. In the safety study with blood biochemical test, it has been shown that all safety parameters in liver were in normal ranges. Also there were no significant changes in the values of the electrolytes, blood lipids profiles, glucose levels and leucocytes number. With these results we have not found any safety problems after the administration of chitosan for 8 weeks. In this study, there was a tendency of immune enhancing effect of chitosan at the experimental dose, which is generally used. More intense clinical study will be needed to confirm statistical significance.
Baek
Kyung Sin
KS
Department of Hygienic Pharmacy and Kyung Hee East-West Pharmaceutical Research Institute, College of Pharmacy, Kyung Hee University, Seoul 130-701, Korea.
Won
Eun Kyung
EK
Choung
Se Young
SY
D000368:Aged; D000369:Aged, 80 and over; D048271:Chitosan / Q000494:pharmacology*; D016207:Cytokines / Q000097:blood*; D006801:Humans; D018664:Interleukin-12 / Q000097:blood; D053583:Interleukin-1beta / Q000097:blood; D007376:Interleukin-2 / Q000097:blood; D015847:Interleukin-4 / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D016207:Cytokines; D053583:Interleukin-1beta; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12; D015847:Interleukin-4; D048271:Chitosan